{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T08:10:03Z","timestamp":1748333403843,"version":"3.41.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T00:00:00Z","timestamp":1736467200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008021","name":"Bristol Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008021","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen Inc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Long-term maintenance of serum urate levels &amp;lt;6\u2009mg\/dl reduces gout flare frequency. However, urate-lowering therapy (ULT) initiation can induce gout flare. The incidence of thromboembolic (TE) and cardiovascular (CV) events has been shown to increase in the 30 and 120\u2009days following gout flare, respectively; therefore, the question of ULT initiation increasing patient risk for CV\/TE events has been raised. Here, we investigate CV\/TE event incidence following pegloticase initiation in clinical trials.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This post hoc analysis of pooled data from four trials examined treatment-emergent gout flare and CV\/TE events in patients with uncontrolled gout. Studies included two phase 3 trials (NCT00325195), the MIRROR open-label trial (NCT03635957), and the MIRROR randomized controlled trial (NCT03994731). Per protocol, pegloticase (8\u2009mg) was administered every 2 (all trials) or 4\u2009weeks (phase 3 trials); data from the first 24\u2009weeks of therapy were included in this analysis. Some MIRROR patients received MTX (15\u2009mg\/week) as co-therapy. Based on prior studies, the high-risk window for CV\/TE events was defined as 120\u2009days following flare onset.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Overall, 5\/328 (1.5%) patients experienced \u22651 CV\/TE event during pegloticase treatment, including 3\/244 (1.2%) patients who received on-label (biweekly) dosing (35.4 events\/1000 person-years). All events occurred within the 120-day gout flare exposure window.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>CV\/TE event incidence during pegloticase treatment was similar to the general gout population (31.7 events\/1000 person-years). These findings suggest that pegloticase initiation does not put patients at a higher risk for CV\/TE events.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaf017","type":"journal-article","created":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T15:10:21Z","timestamp":1736521821000},"page":"3328-3333","source":"Crossref","is-referenced-by-count":0,"title":["Treatment-emergent major adverse cardiovascular and thromboembolic events were infrequent during clinical trials of pegloticase"],"prefix":"10.1093","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-3956-0253","authenticated-orcid":false,"given":"Orrin M","family":"Troum","sequence":"first","affiliation":[{"name":"Division of Rheumatology, University of Southern California Keck School of Medicine and Providence Saint John\u2019s Health Center , Santa Monica, CA,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mai","family":"Duong","sequence":"additional","affiliation":[{"name":"Amgen Inc. , Thousand Oaks, CA,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katie","family":"Obermeyer","sequence":"additional","affiliation":[{"name":"Amgen Inc. , Thousand Oaks, CA,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4199-4844","authenticated-orcid":false,"given":"Lissa","family":"Padnick-Silver","sequence":"additional","affiliation":[{"name":"Amgen Inc. , Thousand Oaks, CA,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7521-241X","authenticated-orcid":false,"given":"Brian","family":"LaMoreaux","sequence":"additional","affiliation":[{"name":"Amgen Inc. , Thousand Oaks, CA,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,1,10]]},"reference":[{"key":"2025052703544169600_keaf017-B1","doi-asserted-by":"crossref","first-page":"e239501","DOI":"10.1001\/jamanetworkopen.2023.9501","article-title":"Trends in prevalence of gout among US Asian adults, 2011\u20132018","volume":"6","author":"Yokose","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2025052703544169600_keaf017-B2","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1093\/rheumatology\/keab539","article-title":"Improving outcomes for patients hospitalized with gout: a systematic review","volume":"61","author":"Russell","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2025052703544169600_keaf017-B3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/PROM.S8310","article-title":"Gout disease-specific quality of life and the association with gout characteristics","volume":"1","author":"Hirsch","year":"2010","journal-title":"Patient Relat Outcome Meas"},{"key":"2025052703544169600_keaf017-B4","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/1477-7525-10-117","article-title":"Tophi and frequent gout flares are associated with impairments to quality of life, productivity, and increased healthcare resource use: results from a cross-sectional survey","volume":"10","author":"Khanna","year":"2012","journal-title":"Health Qual Life Outcomes"},{"key":"2025052703544169600_keaf017-B5","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1093\/rheumatology\/keac706","article-title":"Factors associated with change in health-related quality of life in people with gout: a 3-year prospective cohort study in primary care","volume":"62","author":"Watson","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"2025052703544169600_keaf017-B6","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.3899\/jrheum.071229","article-title":"quality of life and disability in patients with treatment-failure gout","volume":"36","author":"Becker","year":"2009","journal-title":"J Rheumatol"},{"key":"2025052703544169600_keaf017-B7","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1136\/annrheumdis-2024-eular.2570","article-title":"Patient-reported quality of life in uncontrolled gout and changes with intensive urate-lowering: comparison of tophaceous and non-tophaceous patients","volume":"83","author":"Edwards","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2025052703544169600_keaf017-B8","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.amjmed.2011.09.033","article-title":"Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007\u20132008","volume":"125","author":"Zhu","year":"2012","journal-title":"Am J Med"},{"key":"2025052703544169600_keaf017-B9","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1136\/annrheumdis-2014-205252","article-title":"Increased risk of vascular disease associated with gout: a retrospective, matched cohort study in the UK clinical practice research datalink","volume":"74","author":"Clarson","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2025052703544169600_keaf017-B10","doi-asserted-by":"crossref","first-page":"e156","DOI":"10.1016\/S2665-9913(23)00338-7","article-title":"Gout and incidence of 12 cardiovascular diseases: a case-control study including 152 663 individuals with gout and 709 981 matched controls","volume":"6","author":"Ferguson","year":"2024","journal-title":"Lancet Rheumatol"},{"key":"2025052703544169600_keaf017-B11","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s40744-020-00260-1","article-title":"Characteristics, comorbidities, and potential consequences of uncontrolled gout: an insurance-claims database study","volume":"8","author":"Francis-Sedlak","year":"2021","journal-title":"Rheumatol Ther"},{"key":"2025052703544169600_keaf017-B12","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1002\/art.42480","article-title":"Risk of venous thromboembolism with gout flares","volume":"75","author":"Cipolletta","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"2025052703544169600_keaf017-B13","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1001\/jama.2022.11390","article-title":"Association between gout flare and subsequent cardiovascular events among patients with gout","volume":"328","author":"Cipolletta","year":"2022","journal-title":"JAMA"},{"key":"2025052703544169600_keaf017-B14","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/art.20405","article-title":"A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy","volume":"51","author":"Shoji","year":"2004","journal-title":"Arthritis Rheum"},{"key":"2025052703544169600_keaf017-B15","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41584-022-00804-5","article-title":"When underlying biology threatens the randomization principle\u2014initial gout flares of urate-lowering therapy","volume":"18","author":"Choi","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"2025052703544169600_keaf017-B16","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1001\/jama.2011.1169","article-title":"Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials","volume":"306","author":"Sundy","year":"2011","journal-title":"JAMA"},{"key":"2025052703544169600_keaf017-B17","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/acr2.11578","article-title":"A randomized, double-blind, placebo-controlled multicenter efficacy and safety study of methotrexate to increase response rates in patients with uncontrolled gout receiving pegloticase: 12-month findings","volume":"5","author":"Botson","year":"2023","journal-title":"ACR Open Rheumatol"},{"key":"2025052703544169600_keaf017-B18","doi-asserted-by":"crossref","first-page":"767","DOI":"10.3899\/jrheum.200460","article-title":"Pegloticase in combination with methotrexate in patients with uncontrolled gout: a multicenter, open-label study (MIRROR)","volume":"48","author":"Botson","year":"2021","journal-title":"J Rheumatol"},{"key":"2025052703544169600_keaf017-B19","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/art.42335","article-title":"A randomized, placebo-controlled study of methotrexate to increase response rates in patients with uncontrolled gout receiving pegloticase: primary efficacy and safety findings","volume":"75","author":"Botson","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"2025052703544169600_keaf017-B20","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s13075-022-02865-z","article-title":"A multicentre, efficacy and safety study of methotrexate to increase response rates in patients with uncontrolled gout receiving pegloticase (MIRROR): 12- month efficacy, safety, immunogenicity, and pharmacokinetic findings during long-term extension of an open-label study","volume":"24","author":"Botson","year":"2022","journal-title":"Arthritis Res Ther"},{"year":"2022","author":"KRYSTEXXA (pegloticase)","key":"2025052703544169600_keaf017-B21"},{"key":"2025052703544169600_keaf017-B22","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S0140-6736(09)60883-7","article-title":"Gout","volume":"375","author":"Richette","year":"2010","journal-title":"Lancet"},{"key":"2025052703544169600_keaf017-B23","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1002\/art.40807","article-title":"Contemporary prevalence of gout and hyperuricemia in the United States and decadal trends: the National Health and Nutrition Examination Survey, 2007\u20132016","volume":"71","author":"Chen-Xu","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2025052703544169600_keaf017-B24","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/j.semarthrit.2020.04.011","article-title":"Pegloticase treatment of chronic refractory gout: update on efficacy and safety","volume":"50","author":"Schlesinger","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"2025052703544169600_keaf017-B25","doi-asserted-by":"crossref","first-page":"105715","DOI":"10.1016\/j.jbspin.2024.105715","article-title":"Monosodium urate crystal depletion and bone erosion remodeling during pegloticase treatment in patients with uncontrolled gout: exploratory dual-energy computed tomography findings from MIRROR RCT","volume":"91","author":"Dalbeth","year":"2024","journal-title":"Joint Bone Spine"},{"key":"2025052703544169600_keaf017-B26","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.3899\/jrheum.111375","article-title":"Improved health-related quality of life and physical function in patients with refractory chronic gout following treatment with pegloticase: evidence from phase III randomized controlled trials","volume":"39","author":"Strand","year":"2012","journal-title":"J Rheumatol"},{"key":"2025052703544169600_keaf017-B27","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1093\/rheumatology\/keac173","article-title":"Dual-energy CT assessment of rapid monosodium urate depletion and bone erosion remodelling during pegloticase plus methotrexate co-therapy","volume":"61","author":"Dalbeth","year":"2022","journal-title":"Rheumatology (Oxford)"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keaf017\/61407323\/keaf017.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/6\/3328\/61407323\/keaf017.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/6\/3328\/61407323\/keaf017.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T07:54:52Z","timestamp":1748332492000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/6\/3328\/7951311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,10]]},"references-count":27,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,1,10]]},"published-print":{"date-parts":[[2025,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaf017","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"type":"print","value":"1462-0324"},{"type":"electronic","value":"1462-0332"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2025,1,10]]}}}